Thereby, patients with IDH-mutated GBM may benefit from glutamine metabolism targeting, since it will efficiently disrupt de novo lipids synthesis, crucial to sustaining cancer cell proliferation and tumor growth [136]. This evidence concerns the gene IDH1 and cancer.